We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Diagnostic Biomarker Predicts Risk of Opisthorchiasis Cholangiocarcinoma

By LabMedica International staff writers
Posted on 10 Mar 2022
Print article
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)
Image: Opisthorchiasis-associated cholangiocarcinoma. (A) Cholangiocarcinoma specimen showing adult worms in the bile duct (blue arrows). (B) Adult Opisthorchis viverrini recovered from the liver (Photo courtesy of Khon Kaen University)

Opisthorchiasis is caused by an infection with fish-borne liver flukes of the genus Opisthorchis. Opisthorchiasis frequently leads to chronic inflammation in the biliary tract and is classified as a group 1 biological carcinogen by the International Agency for Research on Cancer as a definitive risk for cholangiocarcinoma (CCA).

Opisthorchiasis infection is considered heavy when there are 10,000-30,000 eggs in one gram of feces. Symptoms of heavier infections with Opisthorchis viverrini may include: diarrhea, epigastric and upper right quadrant pain, lack of appetite (anorexia), fatigue, yellowing of the eyes and skin (jaundice) and mild fever.

Parasitologists at the Khon Kaen University (Khon Kaen, Thailand) included in a study 103 serum samples. These sera were assigned to three groups as follows: group I, CCA group (n = 36); group II, other cancers and liver cirrhosis group (n = 47) including hepatocellular carcinoma (n = 28), liver cirrhosis (n = 4), colorectal cancer (n = 8), and brain cancer (n = 7); and group III, other healthy individuals (n = 20). The scientists used the rapid immunochromatographic test (ICT) to detect anti-Opisthorchis viverrini IgG and IgG4 subclass antibodies in sera of patients with CCA. The ICT kits were developed based on soluble antigens excreted and secreted by O. viverrini adult worms.

The investigators reported that ICT indicated sera was positive for IgG and IgG4 antibodies, respectively, in 22 (61.1%) and 15 (41.6%) participants of the 36 study participants diagnosed with CCA. The study also included groups with other cancers and with liver cirrhosis, where the IgG ICT and IgG4 ICT kits were 27.7% (13/47) and 25.5% (12/47) positive, respectively. Neither total the IgG ICT nor the IgG4 ICT yielded positive results in a control group of 20 healthy participants. Moreover, the percentage positivity rate using the ICT for total IgG between the CCA group and the other cancers and liver cirrhosis group was significantly different. By contrast, no significant difference between these groups was apparent in the ICT for IgG4 antibody. The CCA group was 6.53 times more likely to have positive anti–O. viverrini IgG antibody (odds ratio 6.53) and 3.27 times more likely to have positive anti–O. viverrini IgG4 antibody (odds ratio 3.27) than the non-CCA group.

The authors concluded that these findings highlighted the diagnostic potential of a rapid ICT platform that uses ES products from O. viverrini flukes for serodiagnosis of opisthorchiasis-associated CCA. The study was published on March 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Khon Kaen University 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
New
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.